Pedro de Noronha Pissarra, PhD
Chief Executive Officer, Chrysea Labs
Pedro de Noronha, PhD, is an established, highly networked and seasoned life-sciences entrepreneur, having a 25-year track record in the biotechnology and healthcare industry.
A graduate and post-graduate of Kings College London, he carried out research at MIT, the Technical University of Denmark (DTU), Técnico Lisbon (IST) and obtained a Master's in Management from UT Texas, Austin.
He founded in 1996 and sold in 2018 the Biotecnol SA Group of companies, Rodon Biologics (sold to the Iberfar Group) and Biotecnol Limited (sold to Chiome, Inc.). Pedro was a Board Member of Vida Rhein SA, part of the Rhein Biotech group, developing hepatitis vaccines (sold to Dynavax, Inc.), and Board Member of 4Tune Engineering, a world-leading company in Industry 4.0 data-driven and risk-analysis driven bioprocessing.
Pedro has collected numerous awards over the years for his pioneering achievements in bioentrepreneurship.